Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1

被引：0
作者：
Tyring, S. [1 ]
Spelman, L. [2 ,3 ]
Igarashi, A. [4 ]
Ohtsuki, M. [5 ]
Li, Q. [6 ]
Mendelsohn, A. [7 ]
Parno, J. [7 ]
Guenthner, S. [8 ]
机构：
[1] Univ Texas Houston, Dept Dermatol, UTHlth, Houston, TX USA
[2] Verac Clin Res, Brisbane, Qld, Australia
[3] Prob Med Res, Waterloo, ON, Canada
[4] NNT Med Ctr Tokyo, Tokyo, Japan
[5] Jichi Med Univ Hosp, Shimotsuke, Tochigi, Japan
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Sun Pharmaceut Ind Inc, Princeton, NJ USA
[8] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2019年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
[21]   Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis [J].
Zheng, Jianfeng ;
Chen, Wenjuan ;
Yi, Xuemei ;
Yu, Ning ;
Ding, Yangfeng ;
Gao, Yunlu .
FRONTIERS IN MEDICINE, 2023, 10
[22]   Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials [J].
Reich, Kristian ;
Papp, Kim A. ;
Blauvelt, Andrew ;
Tyring, Stephen K. ;
Sinclair, Rodney ;
Thaci, Diamant ;
Nograles, Kristine ;
Mehta, Anish ;
Cichanowitz, Nicole ;
Li, Qing ;
Liu, Kenneth ;
La Rosa, Carmen ;
Green, Stuart ;
Kimball, Alexa B. .
LANCET, 2017, 390 (10091) :276-288
[23]   Tildrakizumab efficacy by metabolic syndrome status in psoriasis: Post hoc analysis of 3-year data from the phase 3 reSURFACE 1 study [J].
Lebwohl, Mark G. ;
Gottlieb, Alice B. ;
Mendelsohn, Alan M. ;
Parno, Jeff ;
Rozzo, Stephen J. ;
Menter, Martin .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) :AB51-AB51
[24]   Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials [J].
Thaci, Diamant ;
Reich, Kristian ;
Lambert, Jo Lydie ;
Iversen, Lars ;
Peserico, Andrea ;
Pau-Charles, Ignasi ;
Blauvelt, Andrew ;
Griffiths, Christopher .
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[25]   Relationships between tildrakizumab dose, exposure, efficacy and safety in phase 3 studies in moderate to severe plaque psoriasis [J].
Strober, Bruce E. ;
Sofen, Howard ;
Yamauchi, Paul S. ;
Mendelsohn, Alan M. ;
Parno, Jeff ;
Lowry, Simon ;
Rozzo, Stephen J. ;
Elewski, Boni E. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) :AB117-AB117
[26]   Tofacitinib in patients with moderate to severe chronic plaque psoriasis: 2-year efficacy and safety in an open-label long-term extension study [J].
Paul, Carle ;
Langley, Richard G. ;
Valenzuela, Fernando ;
Cather, Jennifer ;
Gardner, Annie ;
Proulx, James ;
Tan, Huaming ;
Wolk, Robert ;
Kaur, Mandeep ;
Rottinghaus, Scott .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) :AB278-AB278
[27]   Impact of body weight on efficacy of tildrakizumab at week 12 in moderate to severe chronic plaque psoriasis [J].
Blauvelt, A. ;
Kimball, A. ;
Papp, K. ;
Reich, K. ;
Tyring, S. ;
Sinclair, R. ;
Thaci, D. ;
Li, Q. ;
Cichanowitz, N. ;
Green, S. ;
La Rosa, C. .
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 :109-110
[28]   Efficacy of tildrakizumab in patients with moderate to severe psoriasis according to disease duration: Pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials at week 28 [J].
Thaci, Diamant ;
Iversen, Lars ;
Pau-Charles, Ignasi ;
Schoenenberger Lopez, Andreu ;
Blauvelt, Andrew ;
Puig, Lluis .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) :AB160-AB160
[29]   Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial [J].
Kim A. Papp ;
Saskia de Vente ;
Jiewei Zeng ;
Mary Flack ;
Byron Padilla ;
Stephen K. Tyring .
Dermatology and Therapy, 2021, 11 :487-497
[30]   Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial [J].
Papp, Kim A. ;
de Vente, Saskia ;
Zeng, Jiewei ;
Flack, Mary ;
Padilla, Byron ;
Tyring, Stephen K. .
DERMATOLOGY AND THERAPY, 2021, 11 (02) :487-497
12345